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Objective: Transurethral resection of prostate (TURP) has long been the gold standard for the manage-
ment of benign prostate enlargement (BPE). Over the years, laser techniques have been developed as
major alternative treatment for BPE. Retrospectively, we compared the preoperative status and surgical
outcomes of conventional TURP with those of high-intensity diode laser vaporization in combination
with bipolar TURP (DV þ bTURP) in patients with BPE who are suffering from refractory acute urinary
retention.
Materials and methods: This is a retrospective chart review study. A total of 60 patients with BPE who
were suffering from refractory acute urinary retention were enrolled between July 2011 and July 2013.
Thirty-four patients were included in the TURP group and 26 in the DV þ bTURP group. Perioperative
parameters, including operation time, hemoglobin decrease, length of hospital stay, and time for catheter
removal, were all recorded. Patients were followed postoperatively with peak ﬂow rate measurement,
international prostate symptom scores, and postvoid residual volume, and all adverse events were also
recorded.
Results: DV þ bTURP was superior to TURP in terms of hospital stay (3.1 d vs. 4.2 d), catheter removal
time (1.3 d vs. 3.2 d), hemoglobin reduction (0.8 g/dL vs. 2.5 g/dL), and fewer adverse events. However, it
was inferior to TURP in terms of operation time (93.2 min vs. 68.5 min). Complications are also com-
parable. No signiﬁcant differences were observed in peak ﬂow rates, international prostate symptom
score, and postvoid residual volume between the two procedures.
Conclusion: DV þ bTURP is comparable with monopolar TURP for relieving acute urinary retention in
men with BPE in terms of complications and functional outcomes. The combined technique can provide
better intraoperative hemostasis and shorter catheterization time, with no signiﬁcant postoperative
irritative symptoms.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute urinary retention (AUR) commonly occurs in the elderly
aged >70 years, and more than 10% of men in their 70s experience
AUR within the next 5 years.1 It is a urologic emergency. Urethral
catheterization or suprapubic cystostomy drainage is needed to
treat this condition. The most common cause of AUR is benignen).
ociation. Published by Elsevier Taprostate enlargement (BPE), and a large prostate will increase the
risk. Transurethral resection of prostate (TURP) has long been the
most commonly performed surgical procedure and also a gold
standard for the management of BPE. Surgical complications of
TURP are more for a prostate volume of >50 mL than for a smaller
volume. In a recent study, BPE patients with AUR who underwent
TURP have been found to be associated with a higher risk of com-
plications than those without AUR.2
Over the years, laser prostate ablation techniques have been
developed as the major alternative treatment for BPE. Chen et al3
introduced a combined technique of high-intensity diode laseriwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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(DVþ bTURP), which could provide better intraoperative hemo-
stasis. We assume that DV þ bTURP can reduce the surgical
morbidity and mortality in BPE patients with AUR. The aim of this
study was therefore to examine whether this combined technique
could reduce mortality and morbidity, by comparing it with TURP
among patients with AUR, and to evaluate functional outcomes.2. Materials and methods
We retrospectively reviewed the data of our patients who were
treated surgically for BPE by diode laser or TURP between July 2011
and July 2013. Patients with a prostate volume of >50 mL who
suffered from refractory AUR prior to surgery were included in this
study. We excluded patients who had prostate cancer proved by
surgical specimens, received prostate or urethral surgery previ-
ously, or suffered from neurogenic bladder dysfunction. Detailed
medical histories, physical ﬁndings, and data of laboratory tests,
including hemogram, test for prostate-speciﬁc antigen (PSA), and
urinalysis, were all collected frommedical charts. Prostate volumes
were measured by preoperative transabdominal ultrasound.2.1. Intervention and technique
All procedures were performed or supervised by a single sur-
geon who is highly experienced in laser surgery of prostate. The
laser surgery was performed using a combination of a side-ﬁre
980 nm high-intensity diode laser (Limmer Laser, Berlin, Ger-
many) and bipolar TURP. Laser power could be set at either a
continuous wave mode or a pulsed mode with a maximum power
of 200 W. After diode laser vaporization, bipolar TURP, with power
settings of 320 W for cutting and 200 W for coagulation, was used
only to remove residual coagulated tissue, as cutting at the depth
beyond this zone could result in further hemorrhage. The TURP
surgery was performed by a monopolar cutting loop with a 26F
continuous irrigation resectoscope. The generator was set at 100W
for coagulation and 130 W for cutting. After both surgeries, a 22F
triple-lumen urethral catheter was indwelled with continuous sa-
line irrigation. After hematuria subsided, the urethral catheter was
removed and saline irrigation was discontinued.Table 1
Demographic data.
Mean (SD) Monopolar
(n ¼ 34)
DV þ bTURP (n ¼ 26) p
Age (y) 72.19 (8.73) 72.81 (9.12) 0.796
AUR episodes 1.68 (0.79) 1.77 (0.82) 0.669
CCI score 0.52 (0.68) 0.73 (0.78) 0.2702.2. Effectiveness and complication measures
In addition to baseline demographic data and perioperative
data, we also evaluated the pre-existing comorbidity using the
Charlson comorbidity index.4 The peri- or post-operative compli-
cations were recorded, including blood transfusions, severe
bleeding requiring reoperation, urinary retention requiring reca-
theterization, or TUR syndrome. All surgical complications of two
groups were graded according to the modiﬁed Clavien system.5 For
measuring the effectiveness, several functional outcomes were
assessed in this study, including the international prostate symp-
tom score (IPSS), the rate of urine ﬂow (Qmax), and postvoid residual
volume (PVR) at baseline and at 6 months of follow-up.Prostate size (mL) 62.45 (16.4) 71.64 (26.69) 0.215
PSA 7.07 (2.95) 5.72 (2.29) 0.312
Baseline Hb (g/L) 13.1 (1.41) 13.2 (1.85) 0.762
IPSS 24.2 (3.2) 25.2 (4.1) 0.307
Qmax (mL/s) 6.4 (1.9) 7.1 (2.3) 0.229
PVR (mL) 177.1 (47.0) 172.5 (66.4) 0.762
AUR ¼ acute urinary retention; CCI ¼ Charlson comorbidity index;
DV þ bTURP ¼ high-intensity diode laser vaporization in combination with bipolar
transurethral prostate resection; Hb ¼ hemoglobin; IPSS ¼ international prostate
symptom score; PSA ¼ prostate-speciﬁc antigen; PVR ¼ postvoid residual volume;
Qmax ¼ peak ﬂow rate; SD ¼ standard deviation.2.3. Statistical analyses
Data are expressed as the mean ± standard deviation and were
analyzed by IBM SPSS Statistics for Windows, version 20.0 (IBM
Corp., Armonk, NY). Parameters were compared between the two
groups by Chi-square test (categorical variables) and the indepen-
dent t test (continuous variables), considering p < 0.05 as a sig-
niﬁcant difference.3. Results
During the study period, a total of 60 patients were enrolled
according to the inclusion and exclusion criteria. Thirty-four pa-
tients were treatedwith TURP and 26with DVþ bTURP. All patients
were already catheterized due to previous AUR in the outpatient
clinic or emergency department. Table 1 lists the demographic data
of the two groups. There was no signiﬁcant difference between the
two groups with regard to patients' age, prostate volume, serum
prostate-speciﬁc antigen value, baseline serum hemoglobin value,
and Charlson comorbidity indexes.
3.1. Perioperative ﬁndings
Perioperative results are shown in Table 2. Compared with the
TURP group, in the DV þ bTURP group, signiﬁcantly more time was
required to perform surgery (p < 0.005), but catheterization time
was signiﬁcantly shorter (p ¼ 0.007) and the decrease in hemo-
globin level was less (p < 0.001).
3.2. Postoperative complications
Table 3 summarizes surgical complications of the two groups,
which were graded according to the modiﬁed Clavien system. This
suggests that the TURP group has a higher number of surgical
complications than the laser group. However, in the absence of
statistically signiﬁcant results, no deﬁnite conclusion can be drawn.
The immediate postoperative sepsis developed in four patients in
the TURP group (11.8%) within 3 days of surgery, but in none of the
patients in the laser group. Three patients (8.8%) in the TURP group
and two (7.1%) in the DV þ bTURP group developed acute epidid-
ymitis within 3 months of follow-up, even after receiving oral
antibiotic prophylaxis. Three patients in the TURP group (8.8%) who
had difﬁculty in voiding and bladder clot tamponade needed
further blood evacuation in the operating room, whereas it
occurred in only one patient in the laser group (3.8%). One patient
in the TURP group had severe water intoxication (TUR syndrome)
with acute renal failure. The patient was transferred to the inten-
sive care unit (ICU) for further care, and it took more than 15 days
for recovery.
3.3. Postoperative follow-up parameters
Table 4 shows that, compared with the baseline data, therewere
signiﬁcant improvements in IPSS, Qmax, and PVR in both groups
(p < 0.01 for each). At the 6-month follow-up, postoperative IPSS,
Qmax, and PVR were comparable between the two groups.
Table 2
Comparison of perioperative ﬁndings.
Mean ± SD TURP DV þ bTURP p
Length of procedure (min) 66.31 ± 27.27 96.15 ± 32.38 <0.005
Resected tissue by TUR (g) 32.2 ± 18.3 22.5 ± 14.9 0.034
Hospitalization stay (d) 4.2 ± 3.34 3.1 ± 1.63 0.076
Time to remove catheter (d) 3.2 ± 2.87 1.3 ± 0.51 0.007
Baseline Hb (g/L) 13.1 ± 1.41 13.2 ± 1.85 0.762
Postop Hb decrease (g/L) 1.49 ± 0.89 0.80 ± 0.67 0.001
DV þ bTURP ¼ high-intensity diode laser vaporization in combination with bipolar
transurethral prostate resection; Hb ¼ hemoglobin; SD ¼ standard deviation; TURP,
transurethral resection of prostate.
Table 3
Peri- and post-operative complications.
Complication n (%) TURP DV þ bTURP p
Grade 1
Urgent incontinence 3 (8.8%) 4 (15.4%) 0.454
Grade 2
Blood transfusion 3 (8.8%) 1 (3.8%) 0.626
Sepsis (<3 d after surgery) 4 (11.8%) 0 0.126
Epididymitis (UTI) 3 (8.8%) 2 (7.1%) >0.99
Inability to voiding
Early (failed TOV) 6 (17.6%) 4 (15.4%) >0.99
Late (AUR) 0 1 (3.8%) 0.433
Grade 3
Bladder blood clot tamponade 3 (8.8%) 1 (3.8%) 0.626
Urethral stricture 0 0
Grade 4
TUR syndrome with ARF 1 (2.9%) 0 >0.99
ARF ¼ acute renal failure; AUR ¼ acute urinary retention; DV þ bTURP ¼ high-in-
tensity diode laser vaporization in combination with bipolar transurethral prostate
resection; TOV ¼ trial of voiding; TURP, transurethral resection of prostate;
UTI ¼ urinary tract infection.
Table 4
Functional outcomes.
Clinical measure Treatment group Baseline 6 mo p
IPSS DV þ bTURP 25.2 (4.1) 8.0 (3.1) 0.266
TURP 24.2 (3.2) 8.7 (2.5)
Qmax (mL/s) DV þ bTURP 7.1 (2.3) 19.1 (2.6) 0.227
TURP 6.4 (1.9) 19.4 (1.6)
PVR (mL) DV þ bTURP 172.5 (66.4) 39.2 (25.0) 0.616
TURP 177.1 (47.0) 35.6 (16.0)
Data are presented as mean (standard deviation).
DV þ bTURP ¼ high-intensity diode laser vaporization in combination with bipolar
transurethral prostate resection; IPSS ¼ international prostate symptom score;
PVR ¼ postvoid residual volume; Qmax ¼ peak ﬂow rate; SD ¼ standard deviation;
TURP ¼ transurethral resection of prostate.
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AUR is a common symptom in patients with BPE. However, re-
fractory AUR was one of the indications for surgical intervention.
Chen et al2 reported in their study that 32.6% of patients had AUR
before TURP. In a prospective multicenter study by Reich et al,6 AUR
would increase the intra- or post-operative morbidity of TURP,
including blood transfusion [odds ratio (OR) 2.59], TUR syndrome
(OR 1.85), surgical revision (OR 1.85), and urinary tract infections
(UTIs; OR 2.29). In order to reduce the morbidity and mortality of
TURP, several laser-type surgical techniques were introduced, such
as potassium titanyl phosphate, diode, holmium, and thulium
lasers.7
Among these lasers, diode laser offers a simultaneous absorp-
tion in water and hemoglobin. Therefore, it had the high simulta-
neous tissue ablation and excellent hemostatic properties in clinical
application.8We proposed that it could reduce intraoperative blood
loss by coagulating most of the blood vessels that supply blood tothe prostatic adenomas in these patients with refractory AUR.
Chiang and Chen9 also reported good ablative and hemostatic
abilities of diode laser.
On the other hand, diode laser vaporization could result in
postoperative irritative symptom due to sloughing tissue (18.2%).10
The combination of diode laser vaporization and bipolar TURP
could provide excellent hemostatic properties and effective
removal of residual necrotic tissue. Chen et al3 introduced this
combination surgery, which is a feasible alternative treatment
strategy in the management of BPE. In this retrospective study, the
demographic data, perioperative data, postoperative complica-
tions, and functional outcomes of TURP and DV þ bTURP were all
compared. Our results revealed that DV þ bTURP could reduce
intraoperative blood loss (0.8 g/dL vs. 1.49 g/dL) and catheterization
time (1.3 d vs. 3.2 d) with comparable functional outcomes as
compared with TURP. Our results are consistent with those of Chen
et al.3 Due to limited patient size, no signiﬁcant difference was
observed with regard to complications. However, these results do
not go against our hypothesis that DV þ bTURP reduced morbidity
of patients with AUR.9 In addition, time of removal of urethral
catheter, which could affect the length of hospital stay, is highly
associated with postoperative hematuria.
With regard to surgical complications, we found that more pa-
tients in the TURP group needed blood transfusion postoperatively
and surgery for blood clot evacuation, although there was no sta-
tistical signiﬁcance. BPE patients with AUR usually have serious
intraoperative bleeding. The more likely explanation is a larger
prostate size or prostate inﬂammation, preoperative catheteriza-
tion, or recurrent urinary tract infection in AUR patients. Reich
et al6 reported that patients with preoperative retention were
found to have a higher resectionweight than the rest of the patients
(31.6 g vs. 27.2 g). Certainmorbidities weremainly caused by severe
perioperative bleeding, including operative blood loss requiring
blood transfusion, bladder clot tamponade, and irrigation ﬂuid
absorption (TUR syndrome). In the study by Chen et al,2 they also
found increased rates of recatheterization and postoperative he-
maturia after TURP in patients in the AUR group. They proposed
that prostate infarction results in fragile vessel, which may lead to
increased postoperative bleeding. Compared with the results of
diode laser enucleation of the prostate (DiLEP) reported by Yang
et al,11 in our study, the combination technique had comparable
hemoglobin drop (0.8 g/dL vs. 0.9 g/dL) and operation time
(96.1min vs. 95.2min, total prostate size 71.6 g vs. 70.0 g). However,
an earlier failure of voiding trial was observed in the diode group of
the current study than DiLEP in the study by Yang et al11 (15.4% vs.
9.5%); this could be explained by the refractory AUR history of our
patients, who might have poorer detrusor muscle function. In
addition, compared with the results of the oyster technique re-
ported in the study of Shih et al,12 a slightly steeper hemoglobin
drop (0.8 g/dL vs. 0.6 g/dL) but reduced operation time (96 min vs.
117 min) were observed in our combination group. However, no
subtrigonal injury occurred in our study, whereas it had occurred in
two of the ﬁrst ﬁve patients in the study of Shih et al.12 This is
becausewe removed tissue by bipolar TURP, which is amore formal
resection technique and easy to learn.
In our hospital, all patients underwent a preoperative urinalysis
study and received empiric antibiotic treatment if UTI was diag-
nosed. Patients without UTI received only antibiotic prophylaxis
since the operative day. In the current study, we found a higher rate
of postoperative sepsis in the TURP group during hospitalization,
but no one developed postoperative sepsis in the DV þ bTURP
group, although all the patients routinely received ﬁrst-generation
cephalosporin as a prophylactic antibiotic during the postoperative
period. The possible explanation for this is that concurrent UTI
occurred in patients with refractory AUR. Intraoperative exposure
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location of bacteria from urine into the blood stream, which causes
septicemia or sepsis postoperatively. Chen et al2 reported higher
rates of UTI (18.9%), septicemia (1.1%), and septic shock (0.3%)
during hospitalization, which occurred in patients with AUR after
TURP. It is consistent with our ﬁndings.
Diode laser vaporization showed good hemostatic property, but
a large coagulation zone and tissue sloughing were noted in several
studies.8,9,13,14 Necrotic tissues were highly associated with post-
operative irritative symptoms. Coagulation depth is related to laser
power setting. Lower laser power would decrease the coagulation
zone, but it would reduce laser vaporization efﬁciency.15 Chen et al3
introduced the combination technique of diode laser and bipolar
TURP. They showed a decreasing rate of postoperative lower urinary
tract symptoms (LUTS) because of the removal of coagulated tissue
by bipolar TURP, compared with that by diode laser alone. It is
noteworthy that we used only bipolar TURP to remove the necrotic
and carbonized prostate tissue. If bipolar TURP is performed
extensively beyond the depth of coagulation zone, it may result in
further hemorrhage and lose the hemostatic property of diode laser.
In the current study, four (15.4%) patients in the laser group expe-
rienced transient urge incontinence during the 1st month after
surgery, but no one had persisting urge incontinence. According to
our experience, irritative symptoms could almost be relieved
within 4 weeks. Rieken et al16 reported that 30.3% and 10.7% of
patients who received diode laser prostatectomy had transient and
persisting urge incontinence. In our study, the failure rate of ﬁrst
trial of voiding after surgery was almost the same between the two
groups (15.4% vs. 17.6%). It may be associated with the refractory
AUR history, which results in detrusormuscle dysfunction or edema
in prostate fossa. One (3.8%) patient in the laser group had post-
operative AUR after discharge. It was associated with the sloughing
of larger devitalized tissue, which obstructed the urethra. This was
also noted in the study by Chen et al.14 No patients needed reop-
eration for residual adenoma at 6-month follow-up.
There are limitations to our study. First, the study design was a
retrospective subgroup analysis. There may be a selection bias
because the choice of surgical modality depended on the patient's
decision. However, because the demographic characteristics of
patients in the two groups were not signiﬁcantly different, selec-
tion bias could be minimized. Second, it is a combined technique.
For patients with a larger prostate volume, we had to spend more
time performing bipolar TURP to remove more necrotic tissue. It is
difﬁcult to spend same time performing bipolar TURP individually.
Third, the limited sample size was not large enough to show the
statistical signiﬁcance. Fourth, the 6-month follow-up was not long
enough to prove the long-term effect and efﬁcacy of the interven-
tion. Further large-scale, prospective studies with long-term
follow-up data are obviously needed to draw a solid conclusion.
5. Conclusion
DV þ bTURP is comparable with TURP for relieving AUR in men
with benign prostate obstruction. It allows earlier catheter removaland hospital discharge, although more operation time is required.
Similar efﬁcacy was observed between the two procedures in terms
of peak ﬂow rates, AUA symptom scores, and postvoid residual
urine volume.
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